The new funding will be used to develop a sample preparation module to concentrate bacteria and increase test sensitivity.
The new recommendation is a positive for Qiagen and Oxford Immunotec, both of which market interferon gamma-release assays.
US civil surgeons screening immigrants for TB will need to perform an IGRA from Qiagen or Oxford Immunotec, instead of the decades-old tuberculin skin test.
Japan's Ministry of Health, Labor and Welfare has approved QuantiFeron-TB Gold Plus (QFT-Plus) as an in vitro diagnostic to detect tuberculosis infection.
A spinout from Arizona State University's Biodesign Institute, the company is developing a MALDI-based blood test to identify patients with active infections.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
The portable device runs an isothermal amplification assay to detect genetic material from strains of tuberculosis in resource limited areas.
The firm expects full-year revenue of between $103 and $103.5 million, compared to a prior guidance of $103.5 to $104.5 million.
The companies are working together to pair Qiagen's QuantiFeron-TB diagnostic test with DiaSorin's Liaison family of automated analyzers.